更新于：2024-11-01

Myeloma recurrence

骨髓瘤复发

更新于：2024-11-01

基本信息

别名

Myeloma recurrence、再発ミエローマ、ｻｲﾊﾂﾐｴﾛｰﾏ

简介-

关联

项与骨髓瘤复发相关的药物

SIM-0500

靶点

BCMA x CD3 x GPRC5D

作用机制

BCMA抑制剂 [+2]

在研机构

先聲藥業集團有限公司 [+1]

原研机构

先聲藥業集團有限公司

在研适应症

多发性骨髓瘤 [+1]

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期1800-01-20

项与骨髓瘤复发相关的临床试验

NCT03664661 / Unknown status临床1期IIT

a Single-center, One Arm, Open Clinical Study of BCMA Nanobody CAR-T Cell in Refractory/Relapsed Myeloma

Evaluation of the safety and efficacy of BCMA nanobody CAR-T cells in relapsed/refractory myeloma

开始日期2018-04-11

申办/合作机构

河南省肿瘤医院

[+1]

NCT00747877 / Unknown status临床3期IIT

Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue.

RATIONALE: Giving chemotherapy and bortezomib before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and bortezomib. It is not yet known whether high-dose melphalan given together with a second stem cell transplant is more effective than low-dose cyclophosphamide in treating patients with relapsed multiple myeloma.
PURPOSE: This randomized phase III trial is studying giving high-dose melphalan together with a second stem cell transplant to see how well it works compared with low-dose cyclophosphamide in treating patients with relapsed multiple myeloma after chemotherapy.

开始日期2008-04-01

申办/合作机构

St James's University Hospital

EUCTR2007-007939-29-IT / Not yet recruiting临床2期IIT

A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN, PREDNISONE AND THALIDOMIDE (LB-MPT)IN ADVANCED, REFRACTORY MULTIPLE MYELOMA PATIENTS. - LB-MPT

开始日期2008-03-06

申办/合作机构-

100 项与骨髓瘤复发相关的临床结果

登录后查看更多信息

100 项与骨髓瘤复发相关的转化医学

登录后查看更多信息

0 项与骨髓瘤复发相关的专利（医药）

登录后查看更多信息

项与骨髓瘤复发相关的文献（医药）

2023-03-01·Journal of Oncology Pharmacy Practice4区 · 医学

Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort

4区 · 医学

Article

作者: Kothari, Jaimal ; Vallance, Grant D ; Srinivasan, Anandagopal ; Tseu, Bing ; Collings, Freya ; Maouche, Nadjoua ; Ramasamy, Karthik ; Leary, Heather

Daratumumab is the first anti-CD38 targeting monoclonal antibody approved as monotherapy in multiply relapsed myeloma patients who progressed following prior treatment with proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs). We present real world data on the efficacy of single agent daratumumab in a cohort of 55 multiply relapsed patients treated in the UK. The median age was 72 years, the majority (96%) received ≥ 3 previous lines of treatment; 54.5% were PI-refractory, 76.4% were IMiD-refractory and 47.2% were double refractory; 20% of patients had high-risk (HR) disease. The overall response rate was 49%. After a median follow up of 9.2 months, the median progression-free survival (PFS) for the total cohort was 5.1 months. Patients who achieved a partial response or better (≥PR) demonstrated a significantly longer PFS compared to those with <PR; 9.8 versus 2.7 months, p < 0.001. Double-refractory patients had an inferior PFS compared to single-refractory patients; 2.7 versus 7.4 months, p = 0.084. High-risk disease was associated with significantly shorter PFS compared to standard-risk (SR); 2.3 versus 6.7 months, p = 0.001. The median overall survival (OS) was 15.9 months. Despite a relatively short PFS seen in the double-refractory and high-risk patients; a favourable median overall survival of 12.9 months was achieved in these groups. Patients who achieved ≥PR, those with a previous objective response to PIs or IMiDs and those with SR disease, all benefited from a significantly longer OS which was not reached. A clear benefit in survival is encouraging in this setting of unmet clinical need and limited treatment options.

2022-09-01·American Journal of Ophthalmology Case Reports

Multifocal recurrence of pleomorphic adenoma of the lacrimal gland

作者: Esmaeli, Bita ; Debnam, J Matthew ; Zhao, Jiawei ; Papp, Alexandra M ; Williams, Michelle D

PurposeTo report two cases of multifocal recurrent pleomorphic adenoma of the lacrimal gland, and to highlight the clinical and magnetic resonance imaging findings.ObservationsThe authors present two patients with recurrent pleomorphic adenoma of the lacrimal gland. During their previous primary surgical resection at outside institutions, one patient reportedly had a macroscopically complete excision, while the second patient had violation of the pseudocapsule. Both patients had multiple recurrent nodular lesions detected on magnetic resonance imaging with extension beyond the surgical field of the primary resection. Both underwent subsequent lateral orbitotomy with resection of all identifiable nodules and histopathology was consistent with pleomorphic adenoma. In one patient, two nodules were found two months after the surgery, which grew slowly over the last four years. The second patient had no clinical or radiologic sign of recurrence at last follow up, three years after resection of multinodular recurrence.Conclusions and importanceThe two cases demonstrate the challenges in the management of multifocal recurrence of lacrimal gland pleomorphic adenoma. The multicentric nature of recurrent lesions in these two cases increase the risk of future recurrence, malignant transformation, and morbidity caused by surgery and radiation. Magnetic resonance imaging is the imaging study of choice, but it may still be inadequate in identifying all the nodules.

2022-01-01·Journal of Investigative Medicine High Impact Case Reports

Secondary Extramedullary Myeloma of the Gallbladder: A Case Report

Article

作者: Kolagatla, Sandhya ; Jenkins, Joshua K. ; Strunk, Haley ; Moka, Nagabhishek ; Smith, Forrest ; Ganti, Subramanya Shyam

Extramedullary myeloma (EMM) is an infrequent but well-established manifestation of multiple myeloma (MM), defined as a soft tissue plasma cell neoplasm without bone marrow involvement. Gallbladder involvement in EMM, however, is a very rare occurrence, with only 8 cases found in the English medical literature. Here, we present a case of an older adult male with a gallbladder mass in the presence of increasing serum kappa light chains after a normal bone marrow biopsy confirmed the complete remission of a previous MM diagnosis. Histopathologic evaluation of a biopsied sample confirmed the mass as an atypical plasma cell neoplasm. Later in his treatment, he developed several firm, smooth, violaceous skin nodules on the torso, which histopathology confirmed as also being atypical plasma cell neoplasms. We aim to contribute to the medical literature by expanding the pool of information regarding EMM of the gallbladder to support future diagnostic and treatment recommendations.